 Agios Pharmaceuticals Inc NASDAQ: AGIO has submitted an FDA marketing application seeking approval for mitapivat to treat adults with pyruvate kinase PK deficiency. The company says, if approved, mitapivat could be the first potentially disease-modifying therapy for PK deficiency. 